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N E U R O P H Y S I O L O G Y
The long noncoding RNA neuroLNC regulates 
presynaptic activity by interacting 
with the neurodegeneration-associated protein TDP-43
S. Keihani1*, V. Kluever1*, S. Mandad1,2, V. Bansal3,4, R. Rahman3, E. Fritsch1, L. Caldi Gomes5,6, 
A. Gärtner7, S. Kügler5, H. Urlaub2,8, J. D. Wren9, S. Bonn3,4, S. O. Rizzoli1,6, E. F. Fornasiero1,6†
The cellular and the molecular mechanisms by which long noncoding RNAs (lncRNAs) may regulate presynaptic 
function and neuronal activity are largely unexplored. Here, we established an integrated screening strategy to 
discover lncRNAs implicated in neurotransmitter and synaptic vesicle release. With this approach, we identified 
neuroLNC, a neuron-specific nuclear lncRNA conserved from rodents to humans. NeuroLNC is tuned by synaptic 
activity and influences several other essential aspects of neuronal development including calcium influx, neuritogenesis, 
and neuronal migration in vivo. We defined the molecular interactors of neuroLNC in detail using chromatin isolation 
by RNA purification, RNA interactome analysis, and protein mass spectrometry. We found that the effects of neuroLNC 
on synaptic vesicle release require interaction with the RNA-binding protein TDP-43 (TAR DNA binding protein-43) 
and the selective stabilization of mRNAs encoding for presynaptic proteins. These results provide the first proof 
of an lncRNA that orchestrates neuronal excitability by influencing presynaptic function.
INTRODUCTION
Long noncoding RNAs (lncRNAs) are defined as RNA transcripts 
longer than 200 nucleotides that show no evidence of protein coding 
potential (1). While initially considered a “noisy” by-product of 
pervasive eukaryotic genome transcription (2), novel roles of lncRNAs 
have begun to emerge, and their investigation is rapidly gaining 
momentum in multiple fields of biology (3). Their significance is 
especially salient in the field of cancer biology, where lncRNAs have 
been found to be excellent biomarkers for predicting phenotypic 
changes in malignancies (4).
In the brain, the high abundance and strict developmental regu-
lation of lncRNAs suggest that these molecules have bona fide 
regulatory functions in neuronal differentiation and possibly play 
a role in the establishment of disease (5, 6). Since lncRNAs can 
be rapidly turned over (7), their function might be of particular 
importance to the swift fine-tuning of synaptic activity during the 
delicate establishment of neuronal circuits and during continuous 
structural plasticity in the brain (8–10). Thus, it is imperative to 
understand the precise biological roles of these molecules in brain 
development and neuronal activation.
Notwithstanding, the importance of lncRNAs in the brain is 
often underestimated because of the inherent difficulty in designing 
coherent experimental strategies. A major confounding factor in 
these studies is the nonstringent transcription of neighboring genes, 
which often leads to false-positive correlations for lncRNAs that 
do not have a “true” molecular function. As a result, the number 
of candidates that need to be screened in these experiments is 
disproportionately high, and they provide relatively few functional 
lncRNAs. Moreover, the heterogeneous nature of the lncRNAs’ 
molecular functions means that their discovery necessitates the 
use of highly complex and often unestablished analysis techniques 
(11). These factors have inarguably hindered the study of lncRNAs, 
despite the biological significance of these molecules.
To gain more insight into the role of lncRNAs in the regulation 
of neuronal activity, here, we have developed a two-step screening 
strategy that lessens the confounding effect of pervasive tran-
scription. Our approach takes advantage of a bioinformatic pre-
selection, which screens for conserved correlation across species, 
followed by an assay for measuring synaptic vesicle (SV) exo- 
endocytosis, where the lncRNAs of interest are overexpressed. 
Because of the initial overexpression, we were able to discard all 
candidates that do not have a “true” molecular function early on 
in our experimental workflow. Our approach has allowed us to 
identify an lncRNA that we named neuroLNC, which is highly 
neurospecific and developmentally regulated and controls several 
crucial aspects of neuronal physiology. We also examined the 
molecular interactions of neuroLNC in detail with omics strategies 
and found that it interacts with the RNA-binding protein TDP-43 
(TAR DNA binding protein-43) and promotes the selective stabili-
zation of mRNAs encoding for presynaptic proteins. We propose 
that neuroLNC orchestrates neuronal excitability and influences the 
posttranscriptional regulation of a set of transcripts by serving as 
a nuclear organizing hub, implicating TDP-43 in the coordination 
of neurotransmitter release. More extensively, neuroLNC may be 
essential for ensuring efficient structural plasticity, and due to its 
interaction with TDP-43, might play a role in the modulation of 
disease states.
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RESULTS
A screening strategy for lncRNAs involved in SV release 
identifies neuroLNC as a critical regulator 
of neurotransmitter release
While the roles of lncRNAs during neurogenesis and in the early 
steps of neuronal development have been more intensively studied 
(12), their importance during terminal differentiation, and in particular, 
in SV exo-endocytosis, is virtually unknown. We thus decided to 
specifically study this process, which arises relatively late during 
neuronal differentiation (13). To this aim, we developed a two-step 
screening strategy for identifying lncRNAs that regulate neurotrans-
mitter release in primary neurons. Our strategy combines an initial 
“guilt by association” bioinformatic approach [global microarray 
meta-analysis (GAMMA)] based on correlation networks constructed 
using public transcriptional data (14) and a subsequent assay for 
measuring SV release based on a genetically encoded reporter 
(Fig. 1A) (15). When applying this approach, our GAMMA query 
yielded a total of 79 lncRNA candidates. We filtered these further to 
include only those transcripts that are distant from protein-coding 
genes conserved in rats, mice, and humans (data S1A). The resulting 
six candidates, detailed in data S1B, were cloned and further tested 
in an SV release assay. This allowed us to identify an lncRNA, 
“uc003wst.1,” which upon overexpression drastically increases the 
release of SVs in primary rat hippocampal neurons [351 and 268% 
increases following 60 and 600 action potentials (APs), respectively; 
Fig. 1, B and C, and fig. S1A], without affecting the total vesicle pool 
size (fig. S1B). This lncRNA only partially overlaps with the previously 
annotated LINC00599, depending on the gene assembly and the 
species analyzed (data S1B). Hence, to avoid confusion, we named 
it “neuroLNC.” Down-regulation of endogenous neuroLNC by short 
hairpin RNAs (shRNAs) resulted in decreased SV release (Fig. 1, D and E, 
and fig. S1, C to G), showing that its expression levels are directly 
related to the extent of neurotransmission.
NeuroLNC is conserved in rodents and humans, and its 
genomic locus is close to miR-124-1
Since lncRNAs can exert their function by influencing the transcripts 
in cis in their close proximity, we characterized the neuroLNC locus 
and its genomic organization in detail. NeuroLNC is highly conserved 
between rat and mouse, showing an overall 90.4% similarity and 87.7% 
identity. Orthologous analysis in rat, mouse, and human shows that 
for all three organisms its sequences have very low coding potential 
(fig. S2A) and that they share two conserved regions (CR1 and CR2) 
with ~80% homology, in agreement with what is observed for other 
notable lncRNAs (fig. S2B) (16). The genomic localization and the 
expression of neuroLNC are conserved among rodents and humans. 
While the gene itself is located on different chromosomes for different 
species, it always shares synteny with miR-124-1, the most abundant 
microRNA (miRNA) expressed in neurons (Fig. 1F and fig. S2, C to E) 
(17). Proximity to an miRNA is expected since regions harboring 
lncRNAs can be organized in complex polycistronic clusters together 
with several miRNAs (18). Yet, despite the fact that there is a correla-
tion between neuroLNC and miR-124-1 expression (Fig. 2A), we 
established that neuroLNC is a separate entity from this miRNA 
(Fig. 2, B and C). For this, we isolated total RNA and genomic DNA 
[as a polymerase chain reaction (PCR) control] from rat. The RNA 
was retrotranscribed with random priming and PCR-amplified to 
reveal the presence of different RNA species. If upon retrotranscription 
the PCR was positive for a specific couple of primers, then it indicated 
that there are RNA molecules spanning the region. On the contrary, 
the absence of amplification suggested that there are no RNAs 
spanning the entire region. In total, eight different couples of primers 
were designed for the region between miR-124-1 and neuroLNC, and 
13 different amplification reactions were tested. While the presence 
of several isoforms of neuroLNC is likely, there is, however, no continuity 
between miR-124-1 and neuroLNC. Moreover, neuroLNC does not 
interfere in cis with either miR-124-1 expression levels or its processing, 
measured by comparing relative levels of its 3p and 5p forms using 
miRNA specific quantitative polymerase chain reaction (miQPCR) 
(Fig. 2, D to F) (19). For the sake of completeness, we also character-
ized the distribution of the transcriptional starting sites (TSS) in the 
miR-124-1/neuroLNC locus. The region harbors at least 30 TSS, which 
give rise to several transcripts in both sense and antisense directions 
with respect to both miR-124-1 and neuroLNC, confirming our PCR 
results (Fig. 2G and data S1C). This observation is also in line with 
what has been previously observed, since several lncRNAs exhibit 
multiple splicing isoforms and TSS, which may contribute to cell 
type–specific or developmental stage–specific events (20). Although 
this complex picture suggests the presence of several neuroLNC iso-
forms, here, we focused on the original neuroLNC as was defined in 
our bioinformatic screening (detailed in data S1B).
NeuroLNC is highly neurospecific, developmentally 
regulated, and activity dependent and influences  
calcium dynamics
We found that neuroLNC expression is highly restricted to the brain 
(Figs. 2A and 3A) and more specifically to the nucleus of neuronal 
cells (Fig. 3, B and C, and fig. S3A), while it is virtually undetectable in 
glial cells and cell lines used for modeling neuronal cells (fig. S3B). 
NeuroLNC is developmentally regulated in vitro since its levels 
initially peak during early development and then even out with aging 
(fig. S3C). In the rat brain in vivo, its expression is highest at P7 and 
is reduced to ~30% of its maximum in adults (fig. S3D). NeuroLNC 
expression in adults can still be detected in human brains as well 
(fig. S3E), suggesting a function that goes beyond differentiation 
and is kept during the entire life span of neurons.
Having confirmed the neurospecificity of neuroLNC and its involve-
ment in terminal neuronal differentiation, we tested whether it could 
also affect presynaptic Ca2+ dynamics. Primary rat hippocampal neurons 
infected with an adeno-associated virus (AAV) overexpressing 
neuroLNC showed a significantly enhanced Ca2+ influx following a 
stimulation of 20 AP at 5 and 10 Hz but not at 80 Hz (Fig. 3D and 
fig. S4, A to C). On the contrary, neuroLNC down-regulation decreases 
the influx of Ca2+ during a prolonged 600-AP stimulation at 20 Hz 
(Fig. 3E). NeuroLNC levels also affect the frequencies of endogenous 
calcium bursts that can be observed in hippocampal cultures (Fig. 3F 
and fig. S4D) (21). Having demonstrated that neuroLNC is linked to 
neuronal activity, we turned to investigating whether the regulation 
of neuronal activity can influence the endogenous expression of 
neuroLNC. We tested this in terminally differentiated neurons 
[>14 days in vitro (DIV)], using single-molecule fluorescence in situ 
hybridization (FISH), and we evaluated whether a modulation of 
neuronal activity has an effect on the number of neuroLNC foci. While 
blocking neuronal activity with either tetrodotoxin (TTX) or 6-cyano- 
7-nitro-quinoxaline-2,3-dione (CNQX) had no direct effect on 
neuroLNC foci numbers, pharmacological intensification of neuronal 
activity with bicuculline or 4-aminopyridine (4-AP) significantly 
increased the number of foci 5 hours after treatment (Fig. 3G).
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Fig. 1. An integrated screening strategy identifies NeuroLNC, a conserved lncRNA that regulates SV release. (A) Scheme depicting the experimental steps of the bio-
informatic strategy and of the SV assay. gDNA, genomic DNA. (B) Quantification of the pHluorin experiments upon the pBI-driven overexpression of the lncRNAs following 60-AP 
field stimulation at 20 Hz. Mean values are plotted (± SEM). The tetanus toxin light chain (TetTxLC) was used as a negative control. Statistical test, one-way analysis of variance 
(ANOVA) followed by Bonferroni’s multiple comparison test versus control (***P < 0.001). (C) Quantification and statistics as in (B), following a 600-AP field stimulation at 20 Hz. 
(D and E) Quantification of the SV exo-endocytosis experiments following either a 60- or 600-AP 20-Hz field stimulation, respectively, upon neuroLNC down-regulation. 
Statistical test, unpaired two-tailed Student’s t test (*P < 0.05 and **P < 0.01). (F) Schematic representation of the genomic locus of neuroLNC for rat, mouse, and human.
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Fig. 2. NeuroLNC and miRNA 124-1 are two separate entities with distinct TSS. (A) Scatter plot showing the expression of neuroLNC and pri-miR-124-1. Since the two 
RNAs are transcribed from nearby genomic regions, we tested the correlation of the expression of the two RNAs (r2 = 0.81). (B) Experimental strategy used to test the 
presence of different RNA transcripts in the region between pri-miR-124-1 and neuroLNC. In the lower panel, the couple of primers used (light gray) and the fragments 
amplified (black) are represented to scale. (C) Results of the experiment exemplified in (B). The upper panel corresponds to the control PCR reaction on genomic DNA, and 
the lower panel shows the amplification of the retrotranscribed brain RNA. The lack of continuity between neuroLNC and mirR-124-1 (regions 2 and 3 and regions 3 and 4) 
indicates separate entities. For details concerning the primer sequences, refer to data S1J. bp, base pair; cDNA, complementary DNA. (D and E) Overexpression of 
neuroLNC in either primary hippocampal neurons (D) or differentiated PC-12 cells (E) does not influence the expression of pri-miR-124-1. The expression level values plotted 
are expressed as a percentage of the AAV-control or the control plasmid. NeuroLNC is significantly overexpressed, but there is no effect on the levels of pri-miR-124-1. 
Statistical tests, two-tailed Student’s t test (*P < 0.05 and **P < 0.01); n.s., not significant. (F) NeuroLNC overexpression does not influence the processing of miR-124-1 and 
the relative levels of its 3p and 5p forms. (G) TSS analysis. The scheme summarizes the observed starting sites, detailed in data S1C.
 o
n







Keihani et al., Sci. Adv. 2019; 5 : eaay2670     18 December 2019






























































































































































































































































































Fig. 3. NeuroLNC is neuron specific and nuclear, regulates presynaptic Ca2+ influx, and is modulated by neuronal activity. (A) Relative expression of neuroLNC in the 
rat central nervous system (CNS) and other tissues, as measured by quantitative real-time PCR (qRT-PCR). Statistical test, one-way ANOVA followed by Bonferroni’s multiple 
comparison test versus all non-CNS samples (***P < 0.001). (B) RNA fluorescence in situ hybridization (RNA-FISH) of neuroLNC on coronal brain slice of rat (P14). Note the 
localization to the nuclei of CA1 neurons in the zoom. Scale bars, 0.5 mm (left); 50 m (right). DAPI, 4′,6-diamidino-2-phenylindole. (C) Combined RNA-FISH and immunofluo-
rescence in primary mixed neuroglial cultures. Note that -III tubulin–positive neurons are neuroLNC positive (left, white arrowhead), while cells positive for the glial marker 
glial fibrillary acidic protein (GFAP) are neuroLNC negative (right, white arrowhead). Scale bars, 10 m. (D) Quantification of Ca2+ influx in primary hippocampal neurons 
upon neuroLNC overexpression following a 20-AP field stimulation at different frequencies. Mean values are plotted (± SEM). Insets indicate the difference in fluorescence 
measured at the maximum peak for each experiment. Statistical test, unpaired two-tailed Student’s t test (*P < 0.05; **P < 0.01; and ***P < 0.001). See fig. S5 for details. 
(E) Quantification of Ca2+ influx as in (D), following shRNA-mediated neuroLNC down-regulation with a 600-AP stimulation at 20 Hz. Upon neuroLNC down-regulation, Ca2+ influx 
is significantly decreased. (F) Physiological (unstimulated) network activity measured in neurons following overexpression or down-regulation of neuroLNC. Overexpression 
increases spontaneous activity, while down- regulation has the opposite effect. Unpaired two-tailed Student’s t test (*P < 0.05). (G) The number of neuroLNC foci following 
activity modulation of neurons. Blocking the activity of neurons with TTX or AP5 + CNQX has no effect. The number of neuroLNC foci is promoted by increasing neuronal 
activity by applying bicuculline or 4-AP. In the upper panels, representative images are shown. Scale bar, 5 m. Normalized averages are shown. One-way ANOVA followed 
by Bonferroni’s multiple comparison test versus control (**P < 0.01).
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NeuroLNC regulates neurite elongation in vitro and neuronal 
migration in vivo
Given the role of lncRNAs and Ca2+ dynamics in neuronal development 
(12, 22) and the maximal expression of neuroLNC in the young brain 
(fig. S3D), it appeared likely that neuroLNC could also influence other 
developmental aspects in neurons. We therefore studied the role of 
neuroLNC in neurite growth in an in vitro assay that is used as a 
paradigm to study early neuronal development. Down-regulation 
of neuroLNC in rat primary hippocampal neurons decreased both 
neurite length and branching (Fig. 4, A and B), while its overexpression 
had the opposite effect (Fig. 4, C and D). As neurite growth is 
instrumental for neuronal polarization and migration (23), we tested 
whether neuroLNC could also influence mouse cortical neuron 
migration in vivo. Following in utero electroporation of shRNA 
constructs under a pol III promoter (U6), the electroporated precursor 
cells in the ventricular zone (VZ) terminally differentiate and become 
neurons. Neurons move to reach their final position in the cortical 
plate (CP), migrating through the subventricular zone (SVZ) and 
intermediate zone (IZ), eventually establishing connections with 
the marginal zone (MZ). NeuroLNC down-regulation decreases the 
migration of neurons in vivo from the VZ to the CP (Fig. 4, E and F). 
NeuroLNC overexpression has the opposite effect, since neurons 
show a more efficient migration pattern from the SVZ with respect 
to the control (Fig. 4, G and H). Together, the results presented so 
far suggest that neuroLNC exerts regulatory effects on the biology of 
neurons at different developmental stages and likely participates in 
the fine-tuning of neurotransmission.
NeuroLNC interacts with DNA regions related to SV release 
and synapse organization
In neurons, lncRNAs may act as scaffolding adaptors in macromolecular 
complexes that finely regulate the execution of gene expression programs 
at different steps of mRNA and protein biogenesis (12). This could 
explain how a single molecular species can influence in trans several 
unrelated mechanisms such as neuritogenesis, calcium signaling, and 
neurotransmitter release. To test this hypothesis, we performed a 
series of experiments aimed at defining the molecular interactors of 
neuroLNC in vivo at the DNA, RNA, and protein level (Fig. 5A). 
Since neuroLNC is strictly nuclear (Fig. 3C), we first applied chromatin 
isolation by RNA purification (ChIRP) (24) from the rat brain cortex 
to identify the genome regions where neuroLNC may perform its 
regulatory function(s).
After confirming the specificity and the reliability of the experimental 
approach (fig. S5A), we found that neuroLNC interacts with the DNA 
regions of 3327 genes (Fig. 5B and data S1D). neuroLNC preferentially 
interacts with intronic regions (82%) and regions in the close vicinity 
of genes (16%), with a preference for upstream regions (Fig. 5B). 
This localization may suggest a function of neuroLNC in the transcrip-
tion and/or splicing of these genes. Gene ontology (GO) analysis of 
the target genes shows that neuroLNC is significantly enriched in 
regions related to glutamate receptor signaling, regulation of membrane 
potential, and synapse organization (Fig. 5C and data S1E). These 
results are in line with the biological phenotype that we observe via 
neuroLNC modulation in neurons.
NeuroLNC binds a subset of mRNAs coding for SV proteins
To define the RNA molecules interacting with neuroLNC, we also 
characterized the RNAs that were coprecipitating during ChIRP in 
an RNA interactome experiment (Fig. 5, D and E, and data S1F). 
NeuroLNC mostly interacts with coding mRNAs (~78% of hits), 
although, the fraction of interacting ncRNAs is higher than expected 
from pure chance (twofold higher, 2 statistic, 43.5; P < 0.0001; 
Fig. 5D). Among the most abundant mRNAs interacting with 
neuroLNC, there are two solute carriers (Slc35a1 and Slc22a12), the 
delta-like canonical Notch ligand 3 (Dll3), and three crucial mRNAs 
of proteins involved in neurotransmitter release (SNAP25, Stx1b, 
and Rab3c; Fig. 5E). The Notch signaling pathways have also been 
previously shown to be a target of LncND, an lncRNA that is enriched 
in radial glial cells in the VZ of the developing human brain (25). 
The fact that the overlap between the DNA-ChIRP and the RNA 
interactome analysis is limited (only 34 mRNAs, including Rab3c 
and Dll3 as detailed in data S1G) might reflect the heterogeneity of 
the complexes in which neuroLNC is involved.
NeuroLNC interacts with TDP-43, and the block of this 
interaction abolishes the effects of neuroLNC 
on neurotransmitter release
To define the protein interactors of neuroLNC, we also performed 
protein mass spectrometry (MS) upon neuroLNC enrichment, as 
previously described (Fig. 5, F and G; fig. S5B; and data S1H) (26). 
The sole highly significant enriched interactor of neuroLNC is the 
RNA-binding protein TDP-43, a central player in the pathogenesis 
of neurodegenerative disorders (27) such as frontotemporal lobar 
degeneration (FTLD; also known as frontotemporal dementia) and 
amyotrophic lateral sclerosis (ALS). We also found another important 
enriched player in ALS, the RNA-binding protein found in sarcoma 
(FUS), just below significance levels (enriched approximately seven 
times, P = 0.058).
Because of the importance of TDP-43, we studied its functional 
interactions with neuroLNC in more detail. We performed RNA 
immunoprecipitation (RIP) from the rat cortex with an antibody 
against TDP-43, and we confirmed that the endogenous TDP-43 in 
the brain is bound to neuroLNC (Fig. 5H and fig. S5C). Since TDP-43, 
which is mainly nuclear, can be delocalized to the cytosol during 
pathological modifications, we tested whether the overexpression of 
neuroLNC can delocalize it from the nucleus, but that was not the 
case (fig. S5D). Last, we tested whether there is any functional interaction 
between neuroLNC and TDP-43 in the same SV assay used in our 
initial SV screening (Fig. 5, I and J). To this purpose, TDP-43 was over-
expressed or down-regulated (fig. S5E) in combination with neuroLNC 
overexpression. Since TDP-43 is known to bind a consensus sequence 
with uridine-guanine (UG)–repeats (28), we also included a mutated 
neuroLNC, where the UG-repeats were substituted (neuroLNCMUT; 
data S1I). Transient overexpression of either neuroLNC or TDP-43 in 
rat neurons increased SV release, as expected from our results, and 
in line with previous results obtained with neurospecific TDP-43 
transgenic mice (29). The effect of neuroLNC was blocked by the 
down-regulation of TDP-43 or by the expression of neuroLNCMUT 
(Fig. 5, I and J). This indicates that at least some of the functions of 
neuroLNC are facilitated by its interaction with TDP-43.
NeuroLNC acts by increasing the levels of mRNA coding 
for SV proteins
Which is the molecular mechanism that allows neuroLNC to modulate 
presynaptic activity? It could be speculated that neuroLNC contributes 
to two distinct regulatory events, one at the level of chromatin, which 
regulates gene expression, and one specifically related to RNA 
biogenesis, splicing, or stabilization, which requires the corecruitment 
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Fig. 4. NeuroLNC influences neurite elongation and branching in vitro and neuronal migration in vivo. (A) Exemplary traces of reconstructed primary hippocampal 
neurons transfected with either scramble shRNAs or a pool of three shRNAs against neuroLNC. White arrowheads indicate position of the cell body, and numbers designate 
different cells. Scale bar, 250 m. (B) Summary of morphometric analysis on reconstructed neurons upon neuroLNC down-regulation. Box plots summarize the data dis-
tribution of ~700 neurites as explained in the methods. Unpaired two-tailed Student’s t test (*P < 0.05; **P < 0.01; and ***P < 0.001). (C) Exemplary traces of reconstructed 
neurons as in (A), but upon neuroLNC overexpression. Scale bar, 250 m. (D) Summary of the morphometric analysis of reconstructed neurons. Tracing and analysis of 
~1000 neurites as in (B). (E) Exemplary confocal images of neuronal cells in E17.5 mouse cortices following E14.5 in utero electroporation (i.u.e.) with either scramble shRNAs 
or the shRNA pool against neuroLNC. Upper-left inset represents the portion of the coronal section imaged. Green fluorescent protein (GFP) was included for visualiza-
tion of electroporated neurons (positive neurons are color-coded in magenta). Scale bar, 100 m. (F) Frequency distribution and quantification of positive neurons upon 
neuroLNC down-regulation from the VZ (1st cortical segment) to the CP (10th cortical segment). Equal bins are used and data indicate mean ± SEM (experimental n = 5 in 
control and 7 in neuroLNC down-regulation). Two-way ANOVA with Bonferroni multiple comparison test for each single bin (*P < 0.05 and **P < 0.01). (G) Exemplary con-
focal images showing neuroLNC overexpression in an i.u.e. designed as in (E). A GFP version of the same plasmid was used as a negative control and coelectroporated for 
identifying positive neurons (color-coded in magenta). Scale bar, 100 m. (H) Frequency distribution and quantification of positive neurons upon neuroLNC overexpression 
performed as in (F). Experimental n = 6 in both control neuroLNC overexpression. Two-way ANOVA with Bonferroni multiple comparison test for single bin pairs (**P < 0.01).
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ChIRP sequencing analysis summary
Top-ranking genes
Rbms3 RNA binding protein
Zbtb7c zinc finger
Sidekick-1 adhesion molecule
par-3 family polarity regulator
BTB domain containing 11
DLG associated protein 1
Glypican 6 (WNT signaling)
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Fig. 5. NeuroLNC interacts in vivo with DNA and mRNA sequences of genes implicated in synaptic transmission, binds TDP-43, and requires its presence for 
modulating SV exocytosis. (A) Experimental workflow. For details and controls, see Materials and Methods and fig. S6. RBP, RNA binding protein. (B) Summary of DNA 
interactors of neuroLNC. All the hits are in data S1D. Among genes, preferentially bound top-ranking are shown in the gray inset. (C) Scatter plot of the false discovery rate 
(FDR, expressed as −log10) and enrichment ratio of the significant GO terms. GO analysis confirms the propensity of neuroLNC to be in proximity of genes related to chemical 
transmission, regulation of membrane potential, and synapse development. For an extensive list of GOs, see data S1E. (D) Summary of RNA targets found in the RNA 
interactome. (E) Summary of most abundant significantly enriched mRNA interactors. All mRNAs are significantly enriched versus the controls (P < 0.01), and >15 counts 
are represented in plot. For a comprehensive list, see data S1F. Among the most enriched mRNAs, three are also significantly enriched in STRING (Search Tool for the 
Retrieval of Interacting Genes/Proteins) analysis (gray inset, FDR < 0.01). (F) Scatter plot of the MS identification of the protein interactors of neuroLNC. TDP-43 is the only 
highly significant hit (P < 0.001). For MS data, refer to data S1H. (G) Enrichment of TDP-43 in MS experiments, detailing the negative controls (oligos against LacZ and no 
probe) and RNA purification performed with neuroLNC oligos upon ribonuclease (RNase) treatment. (H) Reverse experiment, where upon immunoprecipitating TDP-43, 
the presence of neuroLNC was tested by qRT-PCR, and the enrichment versus the housekeeping mRNA glyceraldehyde phosphate dehydrogenase (GAPDH) was calculated. 
Ab, antibody; IgG, immunoglobulin G. (I and J) Quantification of the SV exo-endocytosis experiments upon pBI-driven overexpression of either TDP-43, its antisense RNA 
(to decrease its levels), neuroLNC, a mutated form of neuroLNC that does not contain UG-repeats and does not bind TDP-43 (neuroLNCMUT), or several combinations of 
these constructs. SV exo-endocytosis as in Fig. 1 (B and C), following either a 60- or 600-AP field stimulation at 20 Hz. Down-regulation of TDP-43 blocks the effects of 
neuroLNC at both 60 and 600 AP. The neuroLNCMUT shows no effect on SV exo-endocytosis. In both schemes below, graph significances are summarized. One-way ANOVA 
followed by Bonferroni’s multiple comparison test (*P < 0.05; **P < 0.01; and ***P < 0.001). LFQ, label-free quantification.
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of TDP-43 to take place. Both of these events might result in the 
specific change of mRNA levels for key proteins in neuronal function. 
We tested this hypothesis by quantitative real-time PCR (qRT-PCR), 
where we examined the synaptic mRNAs that were mostly affected 
by AAV-mediated neuroLNC overexpression. When taken singularly, 
only SNAP25 and Syntaxin-1a were significantly, although modestly, 
increased (Fig. 6). As a side observation, because of the role of 
SNAP25 in the control of voltage-gated calcium channels (30), at least 
some of the observed calcium effects might be directly influenced 
by the differential expression of SNAP25. The class of mRNAs coding 
for SV proteins and SV protein–associated proteins was, as a whole, 
significantly increased upon neuroLNC overexpression (Fig. 6), while 
all other classes of synaptic and activity-related mRNAs tested were 
indistinguishable from the control (fig. S6).
DISCUSSION
The complex developmental programs of neurons rely on finely tuned 
regulatory mechanisms, which shape the architecture of brain 
circuits during synapse formation and stabilization. The establishment 
of neurotransmission, exemplified by SV exo-endocytosis and 
neurotransmitter release, has a direct influence on these regulatory 
mechanisms (31). Previous studies have revealed that hundreds of 
lncRNAs are dynamically regulated during neuronal development, 
brain activity, and synapse plasticity (5, 32, 33). Nevertheless, these 
observations often lack a causal relationship, and a direct link between 
lncRNA expression and SV exo-endocytosis has never been previously 
elucidated. To study this issue in detail, here we designed a strategy 
comprising a bioinformatic approach and a subsequent biological 
assay that quantifies SV release. Our strategy allowed us to identify 
neuroLNC, a nuclear lncRNA that not only regulates SV release but 
also influences other key aspects of neuronal physiology such as 
Ca2+ dynamics, neurite growth, and neuronal migration.
The initial bioinformatic strategy that we used enabled us to narrow 
down the most promising candidates that we then studied in detail 
with more time-consuming techniques on primary neurons. An 
obvious downside of our approach is that, although we specifically 
searched for keywords related to neurotransmission and brain 
plasticity, there is no direct correspondence between the broad terms 
used in the literature and the phenotypic behaviors of cells. This 
might explain why at the completion of our screening only one of 
the candidates turned out to influence the SV recycling assay that 
we used. Some of the search terms that are used for the bioinformatic 
screening may encompass different molecular mechanisms. Thus, 
we cannot exclude that some of the lncRNAs that we initially selected 
can still influence aspects of neuronal physiology that were not 
revealed by our biological validation. An obvious improvement for 
similar bioinformatic strategies would be to sample literature terms 
directly linked to more technical experimental aspects. At the same 
time, since we lack highly standardized experimental procedures 
for the moment, this might not improve the discovery success rate 
of the approach. Despite these limitations, the dual strategy that we 
describe here can be adapted to individual experimental needs and 
has the potential of serving as a blueprint for several future lncRNA 
studies.
Our screening led to the identification of neuroLNC, an activity- 
dependent lncRNA, which is developmentally regulated and localizes 
to the nucleus of neurons. One of the criteria that we used for the 
refinement of the initial bioinformatic results was a certain degree 
of conservation between humans and rodents, which would suggest 
that neuroLNC function is also conserved across species. An important 
observation is that, in contrast to several other developmentally 
regulated lncRNAs, its expression persists throughout adulthood, 
as observed in rat and human. This indicates that its role might 
be maintained in adult neurons, where it may contribute to activity 
regulation and structural plasticity. While this initial work focused 
on the developmental aspects of neuroLNC, future experiments will 
be necessary to elucidate its role in synapse maintenance and 
presynaptic plasticity.
Because of the large structural heterogeneity of lncRNAs, their 
mechanisms of action are extremely diverse (11). Natural antisense 
transcripts (NATs) are one of the most characterized subclasses of 
lncRNAs since they target protein-coding genes and directly destabilize 
















































































































































Fig. 6. NeuroLNC overexpression increases the levels of SV protein and SV protein–associated mRNAs. Results of the qRT-PCR following overexpression of neuroLNC 
in primary hippocampal neurons with an AAV. Data were GAPDH-normalized and expressed as relative increase with respect to the control cultures (infected with a 
control AAV). Considering individual mRNA species, only SNAP25 and Stx1a are significantly increased across all tested SV and SV-associated mRNAs. Statistical test, one-way 
ANOVA followed by Bonferroni’s multiple comparison test versus controls (**P < 0.01). An overall analysis of the relative expression of all the SV and SV-associated mRNAs 
against their expression in the controls shows a highly significant increase of the whole class (8.2 ± 1.8% increase), suggesting that the effect on all these mRNAs has a 
limited amplitude but is overall consistent, and single significant differences are probably too small to emerge because of the modest sampling depth. Statistical test, 
two-tailed Student’s t test (***P < 0.001).
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notable examples include the mRNA of the brain-derived neurotrophic 
factor (BDNF) and of the potassium voltage-gated channel A2 (KCNA2), 
which are targeted by two NATs (BDNF-AS and KCNA2-AS) and 
influence neuronal activity through a direct control of their respective 
mRNAs (9, 34). We excluded the possibility that neuroLNC acts as 
a NAT by characterizing in detail the genomic region from which it 
originates.
Our data show that neuroLNC is harbored in the vicinity of miR-124-1, 
but it is transcribed from an independent TSS and does not influence 
the stability or the processing of the neighboring miRNA (Fig. 2). 
For these reasons, neuroLNC should be defined as a large/long 
intergenic or intervening ncRNA. It is possible to speculate that the 
regulation of neuroLNC itself might take advantage of an antisense 
mechanism, since we also found some transcripts arising from the 
opposite direction in the neuroLNC locus. This remains for the 
moment hypothetical, although it is particularly interesting since it 
might be the basis of the feedback mechanism regulating its level 
during neuronal hyperactivation (Fig. 3G).
For lncRNAs that do not overlap as an antisense with a protein- 
coding mRNA in cis, defining the molecular mechanism of action 
remains extremely challenging (35), as also evidenced by the fact 
that the function of most lncRNAs remains unknown. One of the 
first steps to define the molecular role of lncRNAs is to identify their 
molecular interactors (11). This task is simplified by the subcellular 
localization of lncRNAs. NeuroLNC is strictly nuclear, and its most 
likely interactors include DNA, RNA, and proteins. We embarked 
in three systematic and unbiased screenings to describe the possible 
interactome of neuroLNC. Our screenings reveal that in vivo, the 
endogenous neuroLNC binds the DNA and the RNA of several 
neuronal genes implicated in neurotransmitter release, synapse 
organization, glutamatergic signaling, and regulation of neuritogenesis. 
While this does not narrow down the number of possible mechanisms 
of action, our findings on the physiology of neurons suggest that 
neuroLNC promotes the transcription of these genes and/or the 
stabilization of the mRNAs that are bound. We are aware that the 
validation of all these possible molecular interactions largely exceeds 
the purpose of this work; thus, we concentrated on the pathways 
that could explain the effects of neuroLNC on neurotransmission. 
We found that some key mRNAs regulating vesicle release such as 
SNAP25 and Syntaxin 1 are increased by overexpression (Fig. 6) and 
are also found interacting with neuroLNC (Fig. 5E). This is critical 
since SNAP25 and Syntaxin 1 are the target SNAREs (soluble 
N-ethylmaleimide–sensitive factor attachment protein receptors) 
promoting SV fusion.
Very few other lncRNAs have been directly linked to both 
neuronal excitability and neuronal growth and development. The most 
notable example is GM12371 (10), which shares several similarities 
with neuroLNC, including activity dependency, nuclear localization, 
and ability to modulate neurite complexity. At the same time, the 
two lncRNAs seem to have completely different mechanisms of 
actions, especially because the effects of GM12371 seem to be linked 
mostly to a postsynaptic phenotype, in contrast with the presynaptic 
modulation induced by neuroLNC.
An important finding is that neuroLNC binds the neurodegeneration- 
associated protein TDP-43 and that neuroLNCMUT, where the UG-repeats 
were substituted, is unable to potentiate SV release. This indicates 
that TDP-43 binding is essential for the activity of neuroLNC, as is 
also reinforced by the observation that the down-regulation of 
TDP-43 abolishes the effects of neuroLNC overexpression. Which is 
the precise molecular pathway that is regulated by the interaction 
between neuroLNC and TDP-43? This question is particularly difficult 
to address, also in light of the fact that TDP-43 modulates multiple 
RNA-related processes in the nucleus. These include the regulation 
of transcription, splicing, and RNA stability, as well as ncRNA 
processing (36). As an example, the activity-dependent lncRNA 
Gomafu might work in a similar manner, since it seems to serve as a 
scaffold that retains splicing factors that are released upon transient 
stimulation (32). Also in the case of Gomafu, the exact mechanism(s) 
of its function are not yet known. Moreover, TDP-43 participates in 
liquid-liquid and liquid-solid phase separation processes, influencing 
the structure of nuclear paraspeckles and of nuclear organization 
(37). NeuroLNC may influence any of these processes and possibly 
function as a scaffold for the assembly of macromolecular complexes 
that define the specificity of TDP-43 for presynaptic mRNAs, which 
result in their selective translation and/or stabilization. All these 
possibilities remain hypothetical and will require future experiments.
Aside from the precise details of the molecular pathway(s) that 
are regulated by the interaction between neuroLNC and TDP-43, one 
can speculate about the possible clinical significance of neuroLNC 
with respect to diseases such as FTLD and ALS. Future studies in 
humans should aim at determining whether neuroLNC expression 
is modified in the early stages of these diseases. Moreover, neuroLNC 
may be included in the detailed panel of DNA sequences analyzed 
in patients with FTLD and ALS. Similarly, it may be worthwhile 
assessing whether overexpression or down-regulation of neuroLNC in 
animal models modulates the development of TDP-43 proteinopathies 
and possibly influences the solubility of TDP-43 and/or modifies its 
interactome. Although promising, clinical applications related to 
neuroLNC should be carefully evaluated and will require future 
validations.
In conclusion, our results suggest that neuroLNC is involved in a 
feed-forward mechanism that enhances neurotransmission through 
the regulation of a subset of synaptic RNAs (summarized in fig. S7). 
More broadly, our work supports the idea that lncRNAs are pertinent 
for the regulation of neurotransmitter release and that their study 




GAMMA is a previously developed algorithm (14) to identify 
correlated transcripts across microarray experiments. After the most 
correlated transcripts are identified, an entity-based literature-mining 
approach (38) is used to analyze their literature commonalities and 
predict ncRNA function. We considered the top 40 most highly 
correlated coding transcripts with the ncRNAs under scrutiny, and 
we analyzed their literature commonalities. These commonalities 
include terms such as diseases, chemicals, phenotypes, other genes, 
cellular functions, cellular structures, and biological processes, 
similar to GO associations. Thus, when function is not known, these 
transcriptional correlation networks can be used to infer function, 
tissue specificity, cellular localization, and phenotype and help 
prioritize experimentation. The use of GAMMA to successfully predict 
mRNA function has been previously reported in several other instances, 
but this is the first successful test of the approach to predict ncRNA 
functions. GAMMA was used to search for uncharacterized non-
coding transcripts associated with the literature annotations: “Brain 
 o
n







Keihani et al., Sci. Adv. 2019; 5 : eaay2670     18 December 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
11 of 16
development,” “Synaptic vesicle,” “Synaptic vesicle exocytosis,” “Synaptic 
vesicle endocytosis,” “Regulation of synaptic plasticity,” “Synapto-
genesis,” “Neurotransmission,” “Dendritic spine,” and “Neuronal 
protein.” These terms were used to define a “Guilt by association 
score” (data S1A) that was used during the first selection round. The 
filters used for scoring the transcripts were (i) low coding potential 
(as previously defined) (39); (ii) conservation across species, defined 
as percentage homology; (iii) distance from the TSS of a known 
annotated protein-coding gene; and (iv) size (sequences longer than 
5 kb were excluded for obvious practical constraints).
Animal and human samples
All animal experiments were approved by the local authority, 
the Lower Saxony State Office for Consumer Protection and Food 
Safety (Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit) and the institutional ethical boards of the 
Katholieke Universiteit Leuven. Mixed neuroglial cultures were 
prepared from P2 Wistar rats. For neuroLNC, cloning and mRNA 
isolation samples were also collected from Wistar rats at various 
ages (as indicated in the respective experiments). For in utero 
electroporation, Swiss mice were used. All human midbrain samples 
were obtained from the Parkinson’s U.K. Brain Bank (Imperial College 
London, London, England). Snap-frozen tissue blocks were transported 
and stored under controlled temperature conditions (−80°C). The 
samples were conceded to the Department of Neurology of the 
University Medical Center Göttingen (Göttingen, Germany), and 
ethical approval was given by the Multicentre Research Ethics 
Committee (07/MRE09/72).
Cell culture and transfections
Mixed hippocampal neuroglial cultures and pure glia cultures 
were prepared from P2 rats as previously described (21). Neurons 
(between 10 and 14 DIVs) were transfected with the calcium-phosphate 
ProFection transfection kit (Promega, Fitchburg, WI, USA) as pre-
viously described (21). The use of this kit increased the reproducibility 
over time. Briefly, cells were incubated for 30 min in 37°C fresh 
Dulbecco’s modified Eagle’s medium (DMEM complemented with 
10 mM MgCl2 and 5 mM Hepes at pH 7.5). For each coverslip, 50 l 
of transfection mixture containing 2.5 g of plasmid DNA, 200 mM 
CaCl2, and 1× Hepes-buffered solution was applied. The cultured 
neurons were incubated with the transfection mixture for 20 min at 
37°C and 5% CO2 followed by three washes with fresh DMEM. Coverslips 
were placed back into their original culture medium and were 
cultured for 3 days at 37°C and 5% CO2 to allow transgene expres-
sion or down-regulation of the targets before further analyses. Hu-
man embryonic kidney (HEK) 293T, C6, and PC-12 cell lines were 
purchased from the German National Resource Center for Bio-
logical Material (DSMZ) and cultured following the recommended 
conditions. For transfection, PC-12 and C6 cells were detached 
by trypsin treatment and transfected using the SF cell line 4D- 
Nucleofector Kit (Lonza) following the instructions of the manu-
facturer. Following electroporation, transfected cells were seeded 
and incubated for 3 days at 37°C. The efficiency of down-regulation 
through TDP-43 antisense (TDP-43-AS) was tested in C6 cells fol-
lowed by qRT-PCR for TDP-43. Differentiation of PC-12 cells was 
induced 1 day after transfection with plates coated with collagen 
(2 g/ml; Roche) by adding 0.1% horse serum and nerve growth 
factor RPMI medium (50 ng/ml). To induce differentiation, PC-12 
cells were cultured in this medium for 7 days, and the medium was 
changed every second day. Differentiation was assessed by morpho-
logical changes (neurite formation).
Plasmids, shRNAs, and DNA cloning
For all the oligonucleotide primers used during cloning, please refer 
to data S1J. Note that all plasmids were confirmed by sequencing 
and, upon reasonable request, they are available from the authors. 
The bidirectional pBI-CMV1 vector was purchased from Clontech 
(CA, USA) and modified with the QuikChange II Site-directed 
mutagenesis kit (Agilent, CA, USA) to delete the Bgl II restriction site 
within the multiple cloning site no. 1 (MCS1). The VAMP-2 pHluorin 
sequence was designed in silico on the basis of a previous publica-
tion (15), and it was ordered at GenScript (USA) and inserted in the 
MCS1 upon digestion with Kpn I and Not I. The plasmid encoding 
for the tetanus toxin light chain (pGEMTEZ-TetTxLC) was a gift 
from R. Jahn. TetTxLC or the six lncRNAs (data S1B) were inserted 
in the MCS2 of the pBI- CMV1-pHluorin plasmid with a PCR strategy 
upon either pGEMTEZ- TetTxLC or Rat genomic DNA amplifica-
tion. The cloning primers used in the PCR strategy for insertion into 
the MCS2 added the following couples of restriction sites during 
amplification: Bcl I/Spe I (for TetTxLC and uc003wst.1), Bgl II/Xba 
I (uc021rvu.1, uc004bbl.1 and uc003jrq.3), Bgl II/Spe I (uc001pyz.3), 
or Bam HI/Xba I (uc004bdv.3). The X1 variant of rat TDP-43 (NCBI 
Reference Sequence: XM_006239382.3) was PCR-amplified from rat 
complementary DNA (cDNA) to add the Xba I and Sac II restric-
tion sites and was inserted into the pBI-CMV1-pHluorin plasmid 
construct. For cloning of TDP-43-AS, the PCR fragment was inserted 
in antisense orientation using Bsu36 I and Sac II restrictions. The 
plasmid ensured an efficient reduction in TDP-43 expression levels with 
respect to control-transfected C6 cells as tested by qRT-PCR (fig. S5E). 
For in utero overexpression, neuroLNC was subcloned into the pCAGEN 
vector (obtained from Addgene) with a PCR strategy adding the Xho I 
and the Not I restriction sites. For viral overexpression, neuroLNC 
was cloned into an AAV backbone that was previously described 
(40) allowing the specific expression in neurons (through the human 
synapsin-1 promoter). For cloning in the viral vector, we used a PCR 
strategy allowing the addition of the restriction sites Asc I (also known 
as Sgs I) and Sbf I (also known as Sda I). Positive viral clones were 
always tested for the integrity of their inverted terminal repeats. For 
down-regulation, shRNAs against rat and mouse sequences were 
designed using the Biosettia tool (available at http://biosettia.com/
support/shrna-designer/, Biosettia, CA, USA) and cloned following 
the manufacturer’s instructions into the pRNA1-M6-green plasmid 
[Biosettia; expressing green fluorescent protein (GFP) concomitantly 
with the shRNA]. As a negative control, the scramble vector provided 
by Biosettia was used. Note that among several tested down-regulation 
methods only the use of the mouse U6 pol-III promoter for the expres-
sion of shRNAs was efficiently down-regulating neuroLNC. The 
neuroLNCMUT sequence was designed in silico (as specified in data 
S1I) and was ordered at GenScript (USA). For all subclonings, we 
relied on commercial chemically competent bacteria (-select bronze 
competent cells, Bioline or SURE bacteria from Agilent in case of 
adeno-associated viral constructs). For transformation, 50 l of 
bacteria was heat-shocked at 42°C for 35 s and cooled briefly before 
addition of 400 l of Super Optimal broth with Catabolite repression 
(SOC) medium (Sigma-Aldrich). After incubation for 45 min at 37°C 
and shaking at 300 rpm, cells were centrifuged and plated on 
agar plates with the appropriate antibiotic selection. Colonies were 
picked on the following morning and grown in LB. Midi preps were 
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prepared using the Macherey-Nagel NucleoBond Xtra Midi EF Kit 
according to the low copy number protocol. DNA was eluted in 
double-distilled ultrapure water (ddH2O). Quality and amount of 
DNA were assessed by NanoDrop 2000 spectrophotometer (Thermo 
Fisher Scientific).
Virus preparation
Recombinant AAV particles were generated as described before (41). 
Briefly, vectors were propagated in HEK293T cells using the pDP6 
helper plasmid (avoiding adenoviral contamination). Viral particles 
were purified by iodixanol step gradient centrifugation followed by 
heparin affinity chromatography. Fast protein liquid chromatography– 
purified/concentrated vectors were desalted by dialysis against 
phosphate-buffered saline (PBS). Viral titer was adjusted by serial 
dilution on primary hippocampal neurons by monitoring GFP 
expression levels (always expressed in a second cassette of the 
construct, driven by the human synapsin-1 promoter).
SV exo-endocytosis evaluation and calcium imaging
SV exo-endocytosis assays were performed as previously described 
(21, 42). Neurons were stimulated with an electric field generated in 
custom-made chambers housing 18-mm coverslips with platinum 
electrodes (8-mm distance between electrodes). For the generation 
of the electrical impulses, we used a Stimulus Isolator combined with 
an A310 Accupulser Stimulator (both from World Precision Instruments, 
USA) with an initial nominal output of 100 mA. Stimulation was 
performed either on neurons expressing the bidirectional series of 
pBI-CMV1-pHluorin plasmids (VAMP-2 based) or coexpressing 
the orange mOr2-Synaptophysin (mOr2-SypHy) indicator of SV 
recycling (21) together with the Biosettia plasmids for down-regulation. 
Coexpression was always confirmed by imaging both the enchanced 
GFP and the mOr2 channel. To test the efficiency of the pBI-CMV1- 
pHluorin plasmids, we included, in the initial screening, a version 
encoding the TetTxLC, which cleaves VAMP-2 and blocks neurotrans-
mitter release. Unless otherwise stated, live experiments were 
performed in Tyrode’s solution [124 mM NaCl, 5 mM KCl, 30 mM 
glucose, 25 mM Hepes, 2 mM CaCl2, and 1 mM MgCl2 (pH 7.4)] 
supplemented with 10 M CNQX (Tocris Bioscience, Cambridge, 
UK) and 50 M 2-amino-5-phosphonopentanoic acid (D-AP5; Tocris 
Bioscience, Cambridge, UK) to avoid spontaneous network activation. 
At the end of each experiment, 50 mM NH4Cl was applied to evaluate 
total SV content. Live imaging was performed with an inverted 
Nikon Ti epifluorescence microscope (Nikon, Tokyo, Japan) equipped 
with a Plan Apochromat 60× 1.4 numerical aperture oil immersion 
objective, an HBO-100W lamp, an IXON X3897 Andor camera 
(Northern Ireland, UK), and an Okolab cage incubator system 
(Okolab, Ottaviano, Italy) to maintain a constant temperature of 
37°C. The system was operated through the NIS-Elements AR software 
(version 4.20; Nikon). ND2 Images were imported using the Bio- 
Formats (Open Microscopy Environment) plug-in. For quantifications, 
the difference in fluorescence intensity before and at the peak of the 
electrical stimulation (F) was normalized to the maximum of 
fluorescence (Fmax) measured upon NH4Cl application. For simplicity, 
all F/Fmax values are expressed as a percentage of the signal measured 
in control cells (either expressing pBI-CMV1-pHluorin or the scramble 
shRNA vector from Biosettia). Each experiment (N) corresponds to 
a different neuronal preparation. For each neuronal preparation, 
the F/Fmax values were collected and averaged from ~500 synapses 
from three or more coverslips. Image analysis was performed by 
identifying the boutons in the exocytotic hotspots with a custom- 
made National Institutes of Health ImageJ macro based on the “Time 
Series Analyzer” ImageJ plugin (available at http://rsbweb.nih.gov/
ij/plugins/time-series.html). For visualization of calcium dynamics, 
neurons were loaded in their own medium for 30 min with the 
acetoxymethyl ester version of Cal-590 (Cal-590-AM; AAT Bioquest), 
a fluorescein-based Ca2+ indicator with single-photon excitation 
and emission peak wavelengths of 570 and 590 nm, respectively. 
After a 10-min reequilibration in their culture medium without 
dye, coverslips were quickly washed in Tyrode’s solution. Neurons 
were imaged and stimulated in the same settings as for the SV 
exo-endocytosis assay. Image analysis measuring signal intensities 
was performed using custom ImageJ macros. Briefly, circular regions 
of interest were placed on transfected cell bodies (identified by the 
GFP signal), and fluorescence was background-corrected. For each 
condition more than eight fields from three different preparations 
were measured. For the analysis of spontaneous activity, cells were 
imaged in the absence of CNQX and D-AP5, peaks surpassing baseline 
noise by at least twofold were recorded, and the frequency was 
determined. For stimulated activity (in the presence of CNQX and 
D-AP5), F was calculated in a 10-s time frame around the stimulation 
maximum. F was then normalized to the baseline signal measured 
just before the beginning of the stimulation (F0). For all experiments 
with neuroLNC overexpression, we also performed the analysis of 
the fluorescence at the peak maximum (which, depending on the 
timing of the imaging and of the stimulation, might be slightly shifted 
in different experiments).
Pharmacology
For the pharmacological modulation of neuronal activity, we used 
1 M TTX (Na+ Channel blocker; Cayman Chemical, USA), 20 M 
bicuculline methobromide (GABAA receptor antagonist; Tocris 
Bioscience, Cambridge, UK), 100 M 4-AP (K+ channel blocker; 
Tocris Bioscience, Cambridge, UK), 10 M CNQX (AMPA/kainate 
receptor antagonist; Tocris Bioscience, Cambridge, UK), and 50 M 
D-AP5 (N-methyl-d-aspartate receptor antagonist; Tocris Bioscience, 
Cambridge, UK). A total of >200 neurons from three different 
cultures were blindly analyzed for each condition.
Neurite elongation assay
Primary hippocampal neuron cultures were transfected at 10 DIVs 
with either a pool of three shRNAs or the pBI construct to down-regulate 
or overexpress neuroLNC, respectively. A total of >20 neurons per 
condition were analyzed following 4 days of expression, from three 
independent cultures. Neurons were manually traced in a blind 
experimental design and analyzed with the ImageJ plugin NeuronJ. 
The aspects considered were the average length and the number of 
primary, secondary, and tertiary neurites (arising respectively from 
the cell body, from a primary neurite, or from a secondary neurite).
In utero electroporation
Pregnant Swiss mice (E14.5) were anaesthetized by intramuscular 
injections of solution containing 117 g of ketamine (Anesketin, 
Eurovet) and 0.7 g of medetomidine hydrochloride (Domitor, Pfizer) 
per gram of body weight. Uterine horns were exposed, and a mixture 
of the required plasmids (1 to 2 g/l) was microinjected with the 
“Fast Green” dye (Sigma-Aldrich) in the lateral ventricles of embryos. 
Five current pulses (50-ms pulse/950-ms interval) were delivered across 
the head of the embryos (36 V), targeting the dorsal-medial part of 
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the cortex. After 3 days of expression, the mothers were euthanized, the 
embryos were dissected, and the brains were quickly perfused with 
PBS and 4% paraformaldehyde (PFA). After dissection, the brains 
were post-fixed for 6 to 10 hours in 4% PFA at 4°C. Vibratome 
sections (100 m) were collected and prepared for imaging. Analysis 
of cell migration was performed as previously described (23) by 
dividing the cortical regions in 10 equal bins and by counting the 
number of positive neuronal nuclei in each bin. Note that also for 
neurons showed in Fig. 4 (E versus G), there are differences in the 
migration of neurons in the controls between experiments, as often 
observed when different control plasmids are used.
Single-molecule RNA in situ hybridization 
and immunofluorescence
FISH was performed with minor modifications from the method 
described in the QuantiGene ViewRNA ISH Cell Assay kit (Affymetrix). 
Briefly, adherent neuronal cultures were washed in Tyrode’s solution 
before being fixed in 4% PFA (Sigma) in PBS. Samples were further 
washed in PBS, and the detergent solution was provided by the 
manufacturer. Specific neuroLNC or glyceraldehyde phosphate 
dehydrogenase (GAPDH) oligonucleotide probes were designed and 
ordered from Affymetrix, diluted in probe diluent solution, and used 
for the hybridization. Coverslips were incubated upside down on 
the probe mix solution in a humidified chamber for 3 hours at 40°C. 
Alternating with washes in SSC buffer (UltraPure SSC, Thermo Fisher 
Scientific), incubation with the preamplifier, amplifier, and label mix 
(1:50 in respective diluent; 30 min at 40°C each) followed. Nuclei were 
stained with DAPI (4′,6-diamidino-2-phenylindole), and coverslips 
were embedded on object slides in Mowiol (Calbiochem, Merck).
Quantitative real-time PCR
For RNA isolation from cells or rodent tissues, the miRNeasy Mini 
Kit (Qiagen) was used. First-strand cDNA was synthesized using 
SuperScript IV (Life Technologies) according to the manufacturer’s 
protocol. For qRT-PCR analyses, the LightCycler 480 SYBR Green I 
Master kit (Roche) was used on a LightCycler 480 Instrument II 
(Roche). All amounts were normalized to their GAPDH controls. 
miRNA expression level was assessed using the miQPCR method as 
previously described (19). For human samples, midbrain blocks were 
transferred shortly to a cryostat for the sake of having controlled 
temperature conditions during sampling (−20°C). Tissue punches 
were extracted from the frozen blocks using a 20-G Quincke Spinal 
Needle (Becton Dickinson), and the sampled material (around 20 mg) 
was stored into ribonuclease (RNAse)/deoxyribonuclease-free tubes. 
Total RNA was isolated from the samples using TRI Reagent (Sigma- 
Aldrich) following the manufacturer’s protocol. RNA precipitates 
were reconstituted in 15 l of nuclease-free water, and the samples 
were cleaned and concentrated using the column-based RNA Clean & 
Concentrator-5 KIT (Zymo Research). RNA (1 g) from each 
patient sample was reverse-transcribed using the QuantiTect Reverse 
Transcription Kit (Qiagen). cDNA samples were diluted 1:3 in 
nuclease-free water and kept at −20°C until further use. For human 
GAPDH, we used the primers “Hs_GAPDH_1_SG” provided in the 
QuantiTect Primer Assay (QT00079247). Unless otherwise stated, 
all other primers used in this study are summarized in data S1J.
Library preparation and sequencing
Library preparation for mRNA sequencing was performed as previously 
described (43). Library preparation for ChIRP sequencing was 
performed according to the NEBNext Ultra DNA Library Prep Kit 
for Illumina (New England BioLabs). Libraries were tested for quality 
and quantified using a NanoDrop 2000 (Thermo Fisher Scientific) 
and an Agilent 2100 Bioanalyzer (Agilent Technologies). Single-end 
50–base pair (bp) sequencing data were generated on an Illumina 
HiSeq2000 using Illumina TruSeq SBS kits.
RNA-sequencing analysis
Quality assessment was based on the raw reads using the FASTQC 
(v0.10.1). The sequence reads (single-end 50 bp) were aligned to the 
rat reference genome (Rnor_6.0) with Bowtie2 (v2.0.2) using RSEM 
(v1.2.29) with default parameters. First, the rat reference genome 
was indexed using the Ensembl annotations (v83.6) with rsem-prepare- 
reference from RSEM software. Next, rsem-calculate-expression was 
used to align the reads and quantify the gene and isoform abundance. 
The output of rsem-calculate-expression separately gives the read 
count and transcripts per million value for each gene and isoform. The 
enrichment was at the end calculated for each biological experiment 
separately as summarized in data S1F. Briefly, the enrichment was 
defined for the odd and the even set separately, and an average 
enrichment was calculated across all enriched conditions.
ChIRP DNA analysis
Data were analyzed as previously described (44). Briefly, reads were 
aligned to the rat reference genome (Rnor_6.0) using Bowtie (v2.0.2) 
with default parameters allowing for two mismatches using seed 
alignment. Subsequently, aligned reads were filtered for high-quality, 
uniquely, and multimapped reads (MAPQ ! = [0, 2, 3, 4]). High-quality 
BAM files were merged for each condition using samtools (v0.1.18). 
Peak calling was performed using MACS2 (v2.1.2) with a minimum 
false discovery rate of 0.05. Peaks were assigned to the genes using 
PAVIS if they were located within 5 kb upstream of the TSS or in the 
transcribed region or within 1 kb downstream of the transcription 
end site.
GO and STRING analyses
GO analysis was conducted using WebGestalt using as a reference 
list all mapped entrez gene IDs from the selected (rnorvegicus) 
genome. For significance, we used an adjusted P value < 0.05 using 
the Benjamini-Hochberg method for controlling the false discovery 
rates during GO terms in biological processes. For details, please refer 
to data S1E. STRING analysis was conducted as previously described 
(43). Also in this case, for testing significance, we relied on an 
adjusted P value < 0.05 using the Benjamini-Hochberg method for 
controlling the false discovery rates.
5′-RACE PCR
For rapid amplification of 5′-cDNA ends, the GeneRacer Kit with 
SuperScript III RT and the TOPO TA Cloning Kit for Sequencing 
(Invitrogen) were used. The gene-specific primers (data S1J) were 
designed for the 5′ end amplification, and nested PCR products 
were cloned and sequenced for analyses as reported in data S1C.
ChIRP and RNA interactome analysis
ChIRP and RNA interactome experiments were performed as 
previously described (24, 26). Antisense oligo probes with 3′ biotin- 
triethyleneglycol modification (TEG) were designed using the online 
probe designer on the ChIRP Probe Designer (version 4.2, LGC Bio-
search Technologies, Middlesex, UK) and synthesized by Sigma-Aldrich 
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(data S1J). Note that the designed primers were blasted against 
whole rat genome and do not specifically bind other targets than 
neuroLNC. The 10 designed probes for neuroLNC were divided into 
two tiling pools (arbitrarily defined odd and even pools). We also 
designed 10 LacZ probes, which served as negative controls. We 
performed the neuroLNC enrichment from the brain of 2-day-old 
(P2) rats where neuroLNC expression is high. For ChIRP, cerebral 
cortices were homogenized with a micropestle in 500 l of ice-cold 
low-sucrose buffer [0.32 M sucrose, 5 mM CaCl2, 5 mM Mg(Ac)2, 
0.1 mM EDTA, 50 mM Hepes (pH 8), 1 mM dithiothreitol (DTT), 
and 0.1% Triton X-100]. Subsequently, the cortex homogenate was 
cross-linked with either 3% formaldehyde or 1% glutaraldehyde 
and sonicated for either 30 or 120 min for either ChIRP MS or 
ChIRP DNA/RNA, respectively. Enrichment of neuroLNC was tested 
by qRT-PCR for ChIRP RNA samples. ChIRP-derived RNA and 
DNA were sequenced, and eluted proteins were analyzed by MS 
proteomics as previously described (43).
MS identification of protein interactors following ChIRP/RNA 
interactome analysis
For proteomic analysis, we initially reversed the cross-linking by 
boiling the beads in a final concentration of 1× NuPAGE LDS Sample 
Buffer (Thermo Fisher Scientific) at 95°C for 30 min on a thermomixer 
(at 750 rpm). After boiling, the samples were loaded on precast 
NuPAGE 4 to 12% Bis-Tris Protein Gels (Thermo Fisher Scientific) 
and separated for 20 min at constant voltage (200 V). The gels were 
stained overnight with Coomassie G250, and for each lane, five to 
six pieces were cut. In-gel digestion was performed overnight using 
trypsin. Samples were dried, and peptides were resuspended in 5% 
acetonitrile and 0.05% trifluoroacetic acid. Samples were further 
processed for liquid chromatography–MS in an online UltiMate 
3000 RSLCnano high-performance liquid chromatography system 
(Thermo Fisher Scientific) coupled online to an Orbitrap Fusion Tribrid 
MS instrument (Thermo Fisher Scientific). Peptides were desalted 
on a reversed-phase C18 precolumn (3 cm long; inner diameter, 100 m; 
outer diameter, 360 m) for 3 min. After 3 min, the precolumn was 
switched online with the analytical column (~30 cm long; inner 
diameter, 75 m) prepared in-house using ReproSil-Pur C18 AQ 
1.9-m reversed-phase resin. The peptides were separated with a 
linear gradient of 5 to 50% buffer B (80% acetonitrile and 0.1% formic 
acid) at a flow rate of 10 nl/min over 58-min gradient time. The 
temperature of the precolumn and the column was set to 50°C 
during chromatography. The MS data were acquired by scanning 
the precursors in a mass range from 380 to 1500 Da at a resolution 
of 120 K at a mass/charge ratio of 200. The acquired RAW data were 
analyzed using MaxQuant software on the basis of the Andromeda 
search engine. The updated rat UniProt database was used for identifying 
proteins (visit the PRIDE dataset identifier PXD013434 for details).
RNA immunoprecipitation
For confirming the interaction between neuroLNC and TDP-43, we 
used a RIP protocol. For this purpose, the cortices of P2 rats were 
homogenized by a micropestle in low-sucrose buffer [0.32 M sucrose, 
5 mM CaCl2, 5 mM Mg(Ac)2, 0.1 mM EDTA, 50 mM Hepes (pH 8), 
1 mM DTT, and 0.1% Triton X-100] on ice. The lysate was cross-
linked by 1% formaldehyde and neutralized with 1.25 M glycine. In 
the following steps, the lysate was washed two times with 1 ml of cold 
Nelson-Jameson buffer (150 mM NaCl, 20 mM EDTA, 50 mM tris, 
0.5% NP-40, and 1% Triton-X-100) and incubated in lysis buffer 
[100 mM tris-HCl (pH 8), 20 mM EDTA, and 2% SDS] for 10 min at 
4°C. The lysate was precleared with Dynabeads protein A (Invitrogen) 
and then incubated with rabbit anti-rat TDP-43 antibody (Proteintech, 
no. 10782-2-AP) or Syntaxin 1A (SYnaptic SYstem, no. 110 302) as 
a negative control overnight and with beads for additional 1.5 hours at 
4°C. After several washing steps, RNA was eluted from beads and purified 
by an miRNeasy Mini Kit (Qiagen). To achieve high-quality samples, 
RNAse inhibitor (SUPERase.In, Invitrogen) and protease inhibitors 
(phenylmethylsulfonyl fluoride and Roche cOmplete EDTA- free protease 
inhibitor cocktail) were added to all solutions. The purified RNA was 
either sequenced or reverse-transcribed for qRT-PCR analyses.
Western blot
Beads derived from ChIP were resuspended in 11 l of Laemmli 
Buffer (4×) and boiled for 30 min at 95°C before dilution with 
water. Western blot for TDP-43 protein was performed using the 
mouse anti-rat TDP-43 (Abcam, no. 104223) and donkey anti-mouse 
IgG IRDye 800CW (Licor).
Immunocytochemistry
Primary neuron coverslips were washed with Tyrode’s solution, fixed 
with 4% PFA for 40 min, and quenched with glycine (1 M) for 
20 min. Afterward, neurons were permeabilized with PBS containing 
0.1% Triton and stained with primary and secondary antibodies in 
PBS containing 1.5% bovine serum albumin and 0.1% Triton for 
1 hour. Mouse anti-rat TDP-43 (Abcam, no. 104223) and donkey anti- 
mouse cyanine3 (Dianova) were used as primary and secondary 
antibodies, respectively. Imaging was performed using an epifluo-
rescence Nikon Eclipse Ti-E microscope equipped with an HBO-
100W Lamp and an IXON X3897 Andor Camera. Capture settings 
were adjusted with the Nikon Imaging Software (NIS Elements).
Statistical analysis and graph construction
Depending on the data, we used Student’s t test or analyses of variance 
(ANOVAs; one or two ways) followed by Bonferroni’s multiple 
comparison post test (as indicated in each figure). Data distribution 
was assumed to be normal. Equal variances were formally tested and 
showed no difference between the groups. No statistical methods were 
used to predetermine sample sizes, and data were collected and pro-
cessed randomly. Data analysis was performed blind to the condition 
when possible, and most of the times experiments were independently 
performed by two or more authors. Box-plot graphs were constructed 
with the box portion of the plot defined by the 25th and the 75th 
percentile, and the line dividing the box corresponds to the median. 
Whiskers indicate the 90th and the 10th percentile.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/12/eaay2670/DC1
Fig. S1. Details of the screening strategy used for studying the role of lncRNAs in neuronal 
activity and down-regulation in culture.
Fig. S2. NeuroLNC coding potential, conservation, and locus organization.
Fig. S3. Specificity of the RNA-FISH approach and expression of neuroLNC in rodent cultures 
and in adult human brain.
Fig. S4. Controls for the calcium dynamics experiments.
Fig. S5. Controls and additional information concerning Fig. 5.
Fig. S6. NeuroLNC overexpression does not affect the expression of the mRNAs that encode for 
calcium-related pathways, neuronal activity, or synaptic scaffolds.
Fig. S7. Schematic representation summarizing the function of NeuroLNC in the nucleus of neurons.
Data S1. Summary of data used here, see first sheet for details.
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